These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11350667)

  • 1. A defined conformational epitope from the C4 domain of HIV type 1 glycoprotein 120: anti-cyclic C4 antibodies from HIV-positive donors magnify glycoprotein 120 suppression of interleukin 2 produced by T cells.
    Robey FA; Robert-Guroff M
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):533-41. PubMed ID: 11350667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-idiotypic antibodies to human anti-gp120 antibodies bind recombinant and cellular human CD4.
    Corre JP; Février M; Chamaret S; Thèze J; Zouali M
    Eur J Immunol; 1991 Mar; 21(3):743-51. PubMed ID: 1672646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.
    Hioe CE; Jones GJ; Rees AD; Ratto-Kim S; Birx D; Münz C; Gorny MK; Tuen M; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):893-905. PubMed ID: 10875615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
    Xiang SH; Doka N; Choudhary RK; Sodroski J; Robinson JE
    AIDS Res Hum Retroviruses; 2002 Nov; 18(16):1207-17. PubMed ID: 12487827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
    Kang CY; Hariharan K; Posner MR; Nara P
    J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression.
    Chien PC; Cohen S; Kleeberger C; Giorgi J; Phair J; Zolla-Pazner S; Hioe CE
    J Infect Dis; 2002 Jul; 186(2):205-13. PubMed ID: 12134256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes.
    Liegler TJ; Stites DP
    J Acquir Immune Defic Syndr (1988); 1994 Apr; 7(4):340-8. PubMed ID: 7907660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A helical epitope in the C4 domain of HIV glycoprotein 120.
    Robey FA; Kelson-Harris T; Roller PP; Robert-Guroff M
    J Biol Chem; 1995 Oct; 270(41):23918-21. PubMed ID: 7592582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects.
    Furci L; Beretta A; Siccardi A; Lazzarin A; Confetti C; Magnani Z; Scarpellini P; Lopalco L; Burastero SE
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1461-9. PubMed ID: 9390745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4.
    Robey FA; Harris-Kelson T; Robert-Guroff M; Batinić D; Ivanov B; Lewis MS; Roller PP
    J Biol Chem; 1996 Jul; 271(30):17990-5. PubMed ID: 8663408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120.
    Denisova G; Raviv D; Mondor I; Sattentau QJ; Gershoni JM
    J Immunol; 1997 Feb; 158(3):1157-64. PubMed ID: 9013955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation.
    Chien PC; Chen D; Chen PD; Tuen M; Cohen S; Migueles SA; Connors M; Rosenberg E; Malhotra U; Gonzalez C; Hioe CE
    J Infect Dis; 2004 Mar; 189(5):852-61. PubMed ID: 14976603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 rgp120 binding to CD4+ T cells by monoclonal antibodies directed against the gp120 C1 or C4 region.
    Kröpelin M; Süsal C; Daniel V; Opelz G
    Immunol Lett; 1998 Aug; 63(1):19-25. PubMed ID: 9719434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.